Brought to you by 
Introgen Therapeutics completes 4.6mm share IPO
16 Nov 2000
Executive Summary
Introgen Therapeutics (gene therapy for cancer) has gone public with an initial public offering of 4.6mm common shares, including the 600k overallotment, at about $8 apiece, bringing in $33.5mm. The company originally filed in February seeking $92mm; then lowered expectations in August when it set a share price of $12-14 each for 5mm shares, looking for $70mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Introgen Therapeutics completes 4.6mm share IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice